ZNTL Valuation

Zentalis Pharmaceuticals Inc

Add to Watchlist

Advanced Chart

1.690

-0.07(-3.977%)1D

Overview
Forecast
Valuation
Earnings

ZNTL Relative Valuation

ZNTL's fair value is calculated using relative valuation, based on historical P/E and P/S ranges and their premiums/discounts relative to a competitor average, adjusted by weights. If the market price exceeds this fair value range, ZNTL is overvalued; if below, it's undervalued.

Historical Valuation

Zentalis Pharmaceuticals Inc (ZNTL) is now in the Fair zone, suggesting that its current forward PS ratio of 0.00 is considered Fairly compared with the five-year average of -6.08. The fair price of Zentalis Pharmaceuticals Inc (ZNTL) is between NaN to NaN according to relative valuation methord.

Relative Value

Fair Zone

NaN-NaN

Current Price：1.69

Fair

-0.84

Trailing

Forward

0.74

EV/EBITDA

Zentalis Pharmaceuticals Inc. (ZNTL) has a current EV/EBITDA of 0.74. The 5-year average EV/EBITDA is -4.25. The thresholds are as follows: Strongly Undervalued below -12.39, Undervalued between -12.39 and -8.32, Fairly Valued between -0.18 and -8.32, Overvalued between -0.18 and 3.89, and Strongly Overvalued above 3.89. The current Forward EV/EBITDA of 0.74 falls within the Overvalued range.

0.89

EV/EBIT

Zentalis Pharmaceuticals Inc. (ZNTL) has a current EV/EBIT of 0.89. The 5-year average EV/EBIT is -4.10. The thresholds are as follows: Strongly Undervalued below -11.86, Undervalued between -11.86 and -7.98, Fairly Valued between -0.22 and -7.98, Overvalued between -0.22 and 3.66, and Strongly Overvalued above 3.66. The current Forward EV/EBIT of 0.89 falls within the Overvalued range.

0.00

Zentalis Pharmaceuticals Inc. (ZNTL) has a current PS of 0.00. The 5-year average PS is 233.11. The thresholds are as follows: Strongly Undervalued below -1839.14, Undervalued between -1839.14 and -803.02, Fairly Valued between 1269.23 and -803.02, Overvalued between 1269.23 and 2305.35, and Strongly Overvalued above 2305.35. The current Forward PS of 0.00 falls within the Historic Trend Line -Fairly Valued range.

-1.08

P/OCF

Zentalis Pharmaceuticals Inc. (ZNTL) has a current P/OCF of -1.08. The 5-year average P/OCF is -6.67. The thresholds are as follows: Strongly Undervalued below -17.18, Undervalued between -17.18 and -11.92, Fairly Valued between -1.42 and -11.92, Overvalued between -1.42 and 3.83, and Strongly Overvalued above 3.83. The current Forward P/OCF of -1.08 falls within the Overvalued range.

-0.91

P/FCF

Zentalis Pharmaceuticals Inc. (ZNTL) has a current P/FCF of -0.91. The 5-year average P/FCF is -6.16. The thresholds are as follows: Strongly Undervalued below -14.67, Undervalued between -14.67 and -10.41, Fairly Valued between -1.90 and -10.41, Overvalued between -1.90 and 2.35, and Strongly Overvalued above 2.35. The current Forward P/FCF of -0.91 falls within the Overvalued range.

Zentalis Pharmaceuticals Inc (ZNTL) has a current Price-to-Book (P/B) ratio of 0.44. Compared to its 3-year average P/B ratio of 1.86 , the current P/B ratio is approximately -76.08% higher. Relative to its 5-year average P/B ratio of 3.81, the current P/B ratio is about -88.33% higher. Zentalis Pharmaceuticals Inc (ZNTL) has a Forward Free Cash Flow (FCF) yield of approximately -123.94%. Compared to its 3-year average FCF yield of -53.14%, the current FCF yield is approximately 133.23% lower. Relative to its 5-year average FCF yield of -34.29% , the current FCF yield is about 261.46% lower.

0.44

P/B

Median3y

1.86

Median5y

3.81

-123.94

FCF Yield

Median3y

-53.14

Median5y

-34.29

Competitors Valuation Multiple

The average P/S ratio for ZNTL's competitors is 11.00, providing a benchmark for relative valuation. Zentalis Pharmaceuticals Inc Corp (ZNTL) exhibits a P/S ratio of 0.00, which is -100.00% above the industry average. Given its robust revenue growth of %, this premium appears unsustainable.

P/S

P/E

EV/EBITDA

EV/EBIT

P/S

Revenue Growth

Market Cap

ZNTL.O

Zentalis Pharmaceuticals Inc

Cardiol Therapeutics Inc

Loss

90.41M

FATE.O

Fate Therapeutics Inc

Molecular Partners AG

Spero Therapeutics Inc

Performance Decomposition

Market capitalization of ZNTL increased by 0.00% over the past 1 year. The primary factor behind the change was an decrease in Unknown from 0.00 to 0.00.

The secondary factor is the Unknown, contributed 0.00%to the performance.

Overall, the performance of ZNTL in the past 1 year is driven by Unknown.